Für Sie Recherchiert 4/2022

Pitfalls in laboratory monitoring of treatment in people with Haemophilia

Lester W., Reilly-Stitt C.
Blood Rev. 2022 55:

Go to publisher for the full text

 

Abstract

A series of cases and scenarios are described to highlight pitfalls in the interpretation of laboratory results in people with haemophilia receiving treatment. This includes assays which grossly exaggerate levels due to in vitro phenomenon and how results which over or under-estimate true values could lead to under or over treatment, unnecessary clinical concern and impact on EQA performance.


Prevalence of pain in adult patients with moderate to severe haemophilia: A systematic review

Ransmann P., Krüger S., Hilberg T., Hagedorn T., Roussel N.
Scand. J. Pain 2022 22:3 (436-444)

Go to publisher for the full text

Abstract

Objectives: Patients with haemophilia (PwH) often suffer from joint pain due to repetitive haemarthroses and resulting arthropathy. Literature focuses so far on pain causes, diagnosis or treatment. A summary of prevalence rates, providing facts on the absolute occurrence of pain, is not sufficiently described so far. This review aimed to explore and systematically review different pain conditions, focussing on prevalence rates of pain in adult PwH. Methods: A review of English articles using PubMed and Web of Science was conducted in February 2020. The search strategy included patients with haemophilia A or B suffering from pain. The articles were selected based on defined PICOS-selection criteria. Results: Out of 606 identified articles, 13 studies matched the given eligibility criteria and indicated pain prevalence rates. The weighted mean (WM) for the prevalence rate (varying timeframes) for chronic pain was 40% whereas for point prevalence the rate was WM=75%. Regarding pain intensity, findings of the EQ-5D-3L revealed moderate pain to be more present (61.0%) compared to extreme (11.6%). The main problem was the inconsistency of the definition of both acute and chronic pain as well as for prevalence types. Conclusions: Pain is a major problem in patients with haemophilia. Pain therapy should be carried out taking into account the difference between bleeding-related or arthropathy-related causes of pain. In addition, the intensity and duration of pain should be recorded consistently to better monitor therapy and allow comparison with existing data.


Treatment Individualization Using Pharmacokinetic Studies and Joint Ultrasound Imaging in Pediatric Patients with Hemophilia

Adramerina A., Teli A., Symeonidis S., Gelsis I., Gourtsa V., Economou M.
J. Pediatr. Hematol. Oncol. 2022 44:5 (237-242)

Go to publisher for the full text

Abstract

Hemophilia is characterized by bleeding diathesis, primarily affecting the joints. Prophylactic use of missing factor aims at limiting the number of bleeds and, in the long term, the risk of permanent joint damage. However, standard prophylactic regimens are usually applied empirically, not adjusting for variations in bleeding phenotype or drug metabolism. Aim of the present study was to evaluate the need for individualizing prophylaxis, with guidance of pharmacokinetic (PK) studies and joint ultrasound in a setting of everyday clinical practice. To evaluate adequacy of applied regimens, joint status was assessed using the Hemophilia Joint Health Score as well as ultrasound imaging, while PK studies were performed using the Web-Accessible Population Pharmacokinetic Service-Hemophilia. Imaging results were consistent with early joint damage in a large proportion of pediatric patients, whereas PK measures were indicative of inadequate prophylaxis in many cases-despite the limited number of bleeds reported by patients. The study revealed the need for prophylaxis adjustment in the majority of patients. Real world data confirm that traditional prophylaxis is often unable to achieve therapeutic goals, while an individualized approach, guided by the use of novel modalities, may be of great benefit to young hemophilia patients.

 


EPH52 Cause-Specific Mortality Among Patients with Hemophilia: A Systematic Review and Meta-Analysis

Sultan I., Syed S.S., Fathima A., Farag H., Yunusa I., Doucette J., Rittenhouse B., Eguale T.
Value Health 2022 25:7 (S444)

Go to publisher for the full text

Abstract

Objectives: Advancing treatment option have improved the life expectancy and decreased mortality related to hemophilia. In the past few decades, a shift has been observed in mortality from bleeding related mortality to comorbidity associated mortality among patients with hemophilia (PwH). The current study aimed to report pooled estimate for cause specific mortality among PwH. Methods: Using search terms related to Mortality and comorbidities in Hemophilia, we conducted a search in Pubmed, Embase and Cochrane databases up to 31 st March 2021. Studies reporting cause-specific mortality in the form of Standardized mortality ratio (SMR) or Hazard ratio (HR) were included in the analysis. Subgroup analysis based on mid-year of data study period (before 2000 and after 2000) was conducted for published studies. Results: A total of 3186 studies were identified and screened. A total of 12 studies reported cause-specific mortality among PwH. The pooled Cardiovascular disease specific SMR was 0.49 (95% CI 0.27-0.88) indicating a 51% decrease in mortality in PwH compared to the general population. The decrease in SMR was consistently observed in studies before 2000 (0.67; 95% CI 0.34-1.30) and after 2000 (0.26; 95% CI 0.14-0.49). Almost 13 folds increase in Liver disease specific SMR was observed in PwH (12.67; 95% CI 6.06-26.47), the Liver disease specific SMR declined over the years (before 2000: 19.07; 95% CI 7.87-46.18; after 2000: 6.31; 95% CI 3.39-11.97). Cancer specific SMR among PwH was 0.80 times lower among PwH (95% CI 0.49-1.30), Cancer specific SMR in PwH before 2000 was 1.01 (95% CI 0.55-1.87) and 0.58 after 2000 (95% CI 0.29-1.19). Conclusions: Different comorbidities have varying impact on PwH’s mortality.

 


Revealing and IgG4 analysis to factor VIII in haemophilia-A patients with and without inhibitors

Awasthi N.P., Tiwari V., Riaz K., Arshad S., Husain N.
Transfus. Apheresis Sci. 2022 61:3

Go to publisher for the full text

Abstract

Introduction: The acquisition of factor VIII inhibitors poses major management challenges for haemophilia A (HA) patients. Most (Factor VIII) inhibitors are immunoglobulin G4 (IgG4) and G1 (IgG1) subclasses, with IgG4 being the most prevalent. The Nijmegen Bethesda Assay (NBA) was used to quantify inhibitors. However, the requirement for a large sample volume, accompanying costs, and required technical expertise complicate NBA, particularly in developing countries. ELISA-based screening proved to be more viable in a resource-constrained scenario. Aim: This study aimed to standardise and evaluate an in-house IgG4 ELISA for the detection of haemophilia A inhibitors. Methods: This study enrolled thirty HA patients with inhibitors, thirty three HA without inhibitors, and 33 healthy controls. Standardisation of in-house IgG4 ELISA was performed. The checkerboard method was employed to optimise plasma-derived Factor VIII concentrations (HEMOFIL M Baxalta US Inc.), sample dilutions, and anti-human IgG4-HRP conjugate (Southern Biotechnology, USA). The samples were evaluated three times, and the mean optical density (OD) was used to determine the cutoff. Results: Using a cutoff OD (mean±2SD) of 0.502 in our in-house ELISA, we could differentiate healthy controls and HA without inhibitors from HA with inhibitors with 93.3 % sensitivity, 97.0 % specificity, 97 % NPV, and 93.3 % PPV, respectively. However, the accuracy was 95.83 %. The two-way mixed-effects model, interclass correlation (ICC) derived by Cronbach's Alpha was 0.912 (p = 0.001) and close to perfect agreement. Conclusions: IgG4 ELISA is an effective method for detecting neutralising or functionally significant FVIII inhibitors, particularly in resource-constrained settings, following which patients may be referred to referral laboratories for quantification of inhibitors.

 


 

New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia

Astermark J., Ay C., Carvalho M., D'Oiron R., Moerloose P.D., Dolan G., Fontana P., Hermans C., Holme P.A., Katsarou O., Kenet G., Klamroth R., Mancuso M.E., Marquardt N., Núñez R., Pabinger I., Tait R., Valk P.V.D.
Thromb. Haemost. 2022 122:6 (905-912)

Go to publisher for the full text

Abstract

Introduction A second peak of inhibitors has been reported in patients with severe hemophilia A (HA) aged >50 years in the United Kingdom. The reason for this suggested breakdown of tolerance in the aging population is unclear, as is the potential impact of regular exposure to the deficient factor by prophylaxis at higher age. No data on hemophilia B (HB) have ever been reported. Aim The ADVANCE Working Group investigated the incidence of late-onset inhibitors and the use of prophylaxis in patients with HA and HB aged ≥40 years. Methods A retrospective, observational, cohort, survey-based study of all patients aged ≥40 years with HA or HB treated at an ADVANCE hemophilia treatment center. Results Information on 3,095 people aged ≥40 years with HA or HB was collected. Of the 2,562 patients with severe HA, the majority (73% across all age groups) received prophylaxis. In patients with severe HA, the inhibitor incidence per 1,000 treatment years was 2.37 (age 40-49), 1.25 (age 50-59), and 1.45 (age 60 +). Overall, the inhibitor incidence was greatest in those with moderate HA (5.77 [age 40-49], 6.59 [age 50-59], and 4.69 [age 60 + ]) and the majority of inhibitor cases were preceded by a potential immune system challenge. No inhibitors in patients with HB were reported. Conclusion Our data do not identify a second peak of inhibitor development in older patients with hemophilia. Prophylaxis may be beneficial in older patients with severe, and possibly moderate HA, to retain a tolerant state at a higher age.

 

 


Real-world rates of bleeding, factor viii use, and quality of life in individuals with severe haemophilia a receiving prophylaxis in a prospective, noninterventional study

Kenet G., Chen Y.-C., Lowe G., Percy C., Tran H., von Drygalski A., Trossaërt M., Reding M., Oldenburg J., Mingot-Castellano M.E., Park Y.-S., Peyvandi F., Ozelo M.C., Mahlangu J., Quinn J., Huang M., Reddy D.B., Kim B.
J. Clin. Med. 2021 10:24

Go to publisher for the full text

Abstract

Regular prophylaxis with exogenous factor VIII (FVIII) is recommended for individuals with severe haemophilia A (HA), but standardised data are scarce. Here, we report real-world data from a global cohort. Participants were men ≥18 years old with severe HA (FVIII ≤ 1 IU/dL) receiving regular prophylaxis with FVIII. Participants provided 6 months of retrospective data and were prospectively followed for up to 12 months. Annualised bleeding rate (ABR) and FVIII utilisation and infusion rates were calculated. Differences between geographic regions were explored. Of 294 enrolled participants, 225 (76.5%) completed ≥6 months of prospective follow-up. Pre-baseline and on-study, the median (range) ABR values for treated bleeds were 2.00 (0–86.0) and 1.85 (0–37.8), respectively; the median (range) annualised FVIII utilisation rates were 3629.0 (1008.5–13541.7) and 3708.0 (1311.0–14633.4) IU/kg/year, respectively; and the median (range) annualised FVIII infusion rates were 120.0 (52.0–364.0) and 122.4 (38.0–363.8) infusions/year, respectively. The median (range) Haemo-QoL-A Total Score was 76.3 (9.4–100.0) (n = 289), ranging from 85.1 in Australia to 67.7 in South America. Physical Functioning was the most impacted Haemo-QoL-A domain in 4/6 geographic regions. Despite differences among sites, participants reported bleeding requiring treatment and impaired physical functioning. These real-world data illustrate shortcomings associated with FVIII prophylaxis for this global cohort of individuals with severe HA.

 

 


 

Psychological interventions for people with hemophilia

Palareti L., Melotti G., Cassis F., Nevitt S.J., Iorio A.
Cochrane Database Syst. Rev. 2020 2020:3

Go to publisher for the full text

Abstract

Background: Managing hemophilia is challenging both in terms of medical treatment and its broad impact on many aspects of the individual's life, including self-perception. Several psychosocial issues are potentially relevant in the clinical management of hemophilia, including it being a chronic and incurable condition; e.g. people with hemophilia must adapt to optimally interact with peers and to practice sports - even choosing a sport represents an issue for perceived limitations, expectations and cultural influences on the individual and their family. People with hemophilia can react by denying their condition and its manifestations and not adhering to treatment. Due to the complexity of relationships surrounding genetic diseases, parents and relatives may have their own issues that contribute to making life easier or more difficult for the person with hemophilia. Anxiety, sadness and depression resulting in mental health disorders are reported in this population and may influence quality of life (QoL) depending on cultural background, religious beliefs, family support and other variables. Objectives: Primarily to assess the effectiveness of psychological therapies for improving the ability of people with hemophilia to cope with their chronic condition. Search methods: We aimed to identify trials from the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register, Embase and PsycINFO, CINAHL, MEDLINE and trial registries. We searched reference lists of included publications. Most recent search of the Group's register: 13 June 2019. Selection criteria: Randomized controlled trials (RCTs) and quasi-RCTs in people with hemophilia of any age or gender, type A or B, any severity, with or without inhibitors, with or without HIV or hepatitis C virus. All psychological interventions for promoting emotional, intellectual and spiritual wellness. Individual, group or family group therapy interventions were eligible. Data collection and analysis: We independently assessed trials, extracted data and assessed the risk of bias and assessed the quality of the evidence using GRADE. Main results: Seven trials were included (362 participants randomized, data from 264 participants available for analysis); six of parallel design and one a partial cross-over design. One multicenter trial was conducted in Canada; the remaining six were single centre undertaken in the UK, USA, Iran and in the Netherlands. All trials had a high risk of bias for participant blinding and use of patient-reported outcomes. Evidence was retrieved on four interventions: psycho-education (DVD plus information booklet versus information booklet alone; computerised learning versus no intervention); cognitive therapy (auto-hypnosis (self-hypnosis) versus control); and behavioural therapy (relaxation (progressive or self control) versus no treatment). We also aimed to assess psychodynamic therapy and systemic therapy, but no trials were identified. Heterogeneity of the outcome measures and measurements precluded meta-analyses. No trial reported the cost of the psychological intervention and family adjustment. DVD plus information booklet compared to information booklet alone. One trial (108 participants) showed coping strategies may lower pre-contemplation scores and negative thoughts, mean difference (MD) -0.24 (95%CI -0.48 - 0.00, low-certainty evidence), however, other measures of coping strategies in the same trial suggest little or no difference between groups, e.g. contemplation, MD (-0.09, 95%CI -0.32 – 0.14, low-certainty evidence). The same trial measured QoL and showed little or no difference between treatment groups for the physical domain, MD 0.59 (95% CI -3.66 to 4.84, low-certainty evidence), but may improve scores in the mental health domain for those receiving the booklet plus DVD compared to booklet alone, MD (4.70, 95% CI 0.33 to 9.07, low-certainty evidence). Mood or personal well-being were not reported. Computerised learning compared to no intervention. Two trials (57 participants) reported on interventions aimed at children and adolescents and their impact on promoting a sense of self-efficacy (primary outcome 'Mood and personal well-being'), but only one showed an increase, MD 7.46 (95%CI 3.21 to 11.71, 17 participants, very low-certainty evidence); the second did not report control group data. One trial (30 participants) showed the intervention did not improve self-efficacy in adults, but appropriate data could not be extracted. Two trials (47 participants) reported coping strategies; one only reported within-group differences from baseline, the second showed an increase from baseline in coping strategies in the Internet program group compared to the no intervention group (disease-specific knowledge, MD 2.45 (95% CI 0.89 to 4.01); self-management ability and transition readiness, MD 19.90 (95% CI 3.61 to 36.19; low-certainty evidence). One trial reported QoL but with insufficient information to calculate changes from baseline; no difference in post-treatment scores was seen between groups, MD -8.65, 95% CI -18.30 to 1.00, very low-certainty evidence). Auto-hypnosis (self-hypnosis) compared to control. There were two older trials that reported on this intervention (50 participants) focusing mainly on the secondary outcome 'physical health'; only one trial reported the primary outcome ‘mood and personal well-being’ (only within-group differences in the treatment group). Coping strategies and QoL were not assessed in the trials. Relaxation (progressive or self control) compared to no treatment. Only one trial (seven participants) from 1985, was included which focused on 'physical health' and did not report on any of our primary outcomes. Authors' conclusions: Not all of the seven included trials analysed the effects of the interventions on our primary outcomes (mood and personal well-being, coping strategies and QoL). Three trials were conducted in the 1970s and 1980s using techniques of auto-hypnosis or relaxation and, in accordance with the needs and therapeutic possibilities of the time, they focused on secondary outcomes, e.g. frequency of bleeding (physical health) and adherence to the intervention. The four newer trials assessed psycho-educational interventions all mediated by the use of technologies (DVD or computer) and often created according to age needs of the target group. In these cases, attention was shifted to our pre-defined primary outcomes. This review has identified low- and very low-certainty evidence, prompting caution in its interpretation. The major problem we encountered was the heterogeneity of trial designs, of interventions and of outcome measures used across the trials. We strongly suggest that researchers consider developing a core outcome set to streamline future research; randomization was proven to be safe and acceptable, and blinding should be considered for those assessing patient-reported outcomes.

 

 

 


Regulation and importance of factor VIII levels in hemophilia A carriers

Cygan P.H., Kouides P.A.
Curr. Opin. Hematol. 2021 28:5 (315-322)

Go to publisher for the full text

Abstract

Purpose of review. To summarize the recent literature related to female hemophilia A carriers with respect to prevalence in the population, the impact of baseline factor VIII levels and other influences on bleeding phenotype, and clinical management needs. Recent findings. Many female hemophilia A carriers are at risk for abnormal bleeding, yet they are underrecognized by healthcare providers and their bleeding symptoms are underreported. Low FVIII levels are consistently associated with clinically significant bleeding and correlate well with skewed X chromosome inactivation (XCI). Most interestingly, bleeding tendency is also observed in some hemophilia A carriers with normal factor VIII levels and requires further investigation. Well controlled studies investigating peripartum and periprocedural FVIII levels and adequate hemostatic treatment are necessary to inform management guidelines. Summary Prevalence and bleeding tendency of hemophilia A carriers remain underreported, despite a significant proportion having low FVIII levels. Skewed XCI may explain low FVIII but does not explain the bleeding risk encountered in a larger proportion of hemophilia A carriers with random XCI and borderline/normal FVIII.

 

 

 


The bleeding phenotype in people with nonsevere hemophilia

Kloosterman F.R., Zwagemaker A.-F., Bagot C.N., Beckers E.A.M., Castaman G., Cnossen M.H., Collins P.W., Hay C., Hof M., Gorkom B.L.-V., Leebeek F.W.G., Male C., Meijer K., Pabinger I., Shapiro S., Coppens M., Fijnvandraat K., Gouw S.C., Fijnvandraat K., Coppens M., Gouw S.C., Leebeek F.W.G., Kruip M., Cnossen M.H., Meijer K., Eikenboom J., Smiers F.J.W., Beckers E.A.M., Nieuwenhuizen L., Brons P., Gorkom B.L.-V., Castaman G., Collins P., Bagot C.N., Hay C., Shapiro S., Boyce S., Male C., Pabinger I., Jackson S.
Blood Adv. 2022 6:14 (4256-4265)

Go to publisher for the full text

Abstract

Detailed information on the onset, frequency, and severity of bleeding in nonsevere hemophilia is limited. We aimed to assess the bleeding phenotype of persons with nonsevere hemophilia and to analyze the association between baseline factor VIII/IX (FVIII/IX) levels and the joint bleeding rate. In the DYNAMO (Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B) study, an international multicenter cohort, we included males with nonsevere hemophilia (FVIII/IX, 0.02-0.35 IU/mL) aged 12 to 55 years. Information on age at first treated (joint) bleed, annual bleeding rates (ABRs), and annual joint bleeding rates (AJBRs) was collected from the medical files. The association between baseline FVIII/IX levels and the joint bleeding rate was assessed by using a frailty model for recurrent events. In total, 304 persons (70 with moderate hemophilia and 234 with mild hemophilia) were included. The median age was 38 years (interquartile range [IQR], 25-49 years), and the median baseline FVIII/IX level was 0.12 IU/mL (IQR, 0.05-0.21 IU/mL). In total, 245 (81%) persons had experienced at least 1 bleed, and 156 (51%) had experienced at least 1 joint bleed. The median age at first bleed and first joint bleed was 8 and 10 years, respectively. The median ABR and AJBR was 0.2 (IQR, 0.1-0.5) and 0.0 (IQR, 0.0-0.2). From baseline FVIII/IX levels 0.02 to 0.05 IU/mL to >0.25 IU/mL, the median ABR decreased from 0.6 (IQR, 0.2-1.4) to 0.1 (IQR, 0.0-0.2) and the AJBR from 0.2 (IQR, 0.0-0.4) to 0.0 (IQR, 0.0-0.0). Baseline FVIII/IX was inversely associated with the joint bleeding rate (P < .001). Low bleeding rates were observed in persons with nonsevere hemophilia. However, one-half of all adolescents and adults had experienced a joint bleed.

 

 

 

 


Low-dose prophylaxis and its impact on the health of haemophilia patients

Shetty S., Bansal S., Kshirsagar S., Rangarajan S., Hajirnis K., Phadke V.
Vox Sang. 2022 117:7 (900-912)

Go to publisher for the full text

Abstract

Background and Objectives: There is convincing evidence to show that low-dose prophylaxis (LDP) results in reduction in annualized bleeding rate (ABR) and better health-related quality of life (HRQoL) compared with on-demand or episodic treatment (ET) in haemophilia patients. The aim is to review various LDP protocols practised for the treatment of haemophilia, specifically in resource-limited countries. Methods: A literature survey was made of articles published in English language in PubMed and EMBASE without any time limit using keywords ‘low dose’, ‘prophylaxis’ and ‘haemophilia’ in different combinations. Results: A total of 19 reports involving LDP in patients with haemophilia were included in this review. Almost all studies reported reduction in ABR, improvement in joint function, pain and HRQoL compared with ET, but this did not fully translate into significant improvement in structural arthropathy already caused by earlier bleeds, suggesting that LDP may be less or ineffective in either stopping or reversing the damage. Individualized dose escalation protocols based on pharmacokinetic (PK) or clinical parameters were found to be superior to fixed LDP protocols and cost-effective compared with standard dose protocols. Conclusion: The developing countries can initiate LDP as the first step of prophylaxis, but certainly this should not be the final goal of the health care system in any country. Due to the complex pathophysiological mechanisms underlying haemophilic arthropathy, long-term data on LDP in haemophilia patients are warranted.

 

 

 

 


Long-term joint outcomes in adolescents with moderate or severe haemophilia A

Schmidt D.E., Michalopoulou A., Fischer K., Motwani J., Andersson N.G., Pergantou H., Ranta S.
[Article in Press] Haemophilia 2022 :

Go to publisher for the full text

Abstract

Introduction: Favourable joint outcomes are expected with modern haemophilia A (HA) management. Evaluation of long-term treatment outcomes is hampered by the delay between bleeding episodes during childhood and resulting joint outcomes in adulthood. Aim: To measure the long-term joint health of adolescents with moderate and severe HA, according to severity and inhibitor status. Methods: Pilot cross-sectional study of five European PedNet centres in moderate and severe HA patients aged 10–19 years. Structured assessment of joint status by physical examination (HJHS) and ultrasound (HEAD-US). Results: In total, 141 HA patients were evaluable, 100 without inhibitors (81 severe, 19 moderate HA), and 41 severe HA with current/past inhibitors. On physical examination, 12/81 (15%) of severe HA without inhibitors, 3/19 (16%) of moderate HA, and 13/41 (32%) of severe HA patients with inhibitors exhibited joint abnormalities. Inhibitor persistence, longer inhibitor duration, and a high peak inhibitor level were associated with impaired joint health. Ultrasound showed joint damage (bone or cartilage) in 13/49 (27%) of severe HA without inhibitors, 1/12 (8%) of moderate HA, and 10/28 (36%) of severe HA patients with inhibitors. A discordant ankle evaluation by ultrasound versus physical examination was present in 53/169 joints (31%). Conclusions: Most adolescents with severe or moderate HA show favourable joint health. Future research with combined ultrasound and/or MRI is needed to better understand joint outcomes in the remaining patients. Patents with inhibitors showed a two-fold increased proportion with joint deterioration. Ultrasound paired with physical examination increases sensitivity for detection of joint damage.

 

 

 

 


Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany?

Hmida J., Hilberg T., Ransmann P., Tomschi F., Klein C., Koob S., Franz A., Richter H., Oldenburg J., Strauss A.C.
Haemophilia 2022 28:4 (663-670)

Go to publisher for the full text

Abstract

Background: In patients with haemophilia (PwH), most frequently affected joints are the ankle, knee and elbow. Due to improved factor therapy in the last decades, these previous findings have to be verified in Germany. Aim: The aim of this study is to detect the most affected joint, evaluate the significance of the source of pain and determine the point prevalence of back pain in Germany today. Patients and methods: In a retrospective study, data of n = 300 patients with severe moderate and mild haemophilia were evaluated regarding the most affected joint, the most common source of pain, and the point prevalence of back pain. An anamnesis questionnaire and the German Pain Questionnaire were used for this assessment. Results: The most affected joint in German PwH is still the ankle (41%), followed by the knee (27%) and the elbow (11%). The most common source of pain is also the ankle joint (32%). Back pain was also identified as one of the most common sources of pain, which is comparable to the elbow (elbow:15%; back:13%). The point prevalence in PwH for back pain was significantly higher compared to the general German population (P =.031). Conclusion: Our data showed that the ankle is still the most affected joint and the most common source of pain in Germany. These results also showed the relevance of back pain as a pain source. The evaluations also demonstrated the high point prevalence of back pain in PwH. Future therapies should also focus on the spine because joint changes affect posture.

 

 

 

 

 


 

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study

Oleshko O., Werwitzke S., Klingberg A., Witte T., Eichler H., Klamroth R., Holstein K., Hart C., Pfrepper C., Knöbl P.N., Greil R., Neumeister P., Reipert B.M., Tiede A.
[Article in Press] Blood Adv 2022:

Go to publisher for the full text

Abstract

The root cause of autoantibody formation against factor VIII (FVIII) in acquired hemophilia A (AHA) remains unclear. We aimed to assess whether AHA is exclusively associated with autoantibodies towards FVIII, or whether patients also produce increased levels of autoantibodies against other targets. A case-control study was performed enrolling patients with AHA and age-matched controls. HEp-2 immunofluorescence was applied to screen for anti-nuclear (ANA) and anti-cytoplasmic autoantibodies. Screening for autoantibodies against extractable nuclear antigens (ENA) was performed by enzyme immunoassay (EIA) detecting SSA/Ro, SSB/La, U1RNP (70 kDa, A, C), Scl-70, JO-1, centromere B, Sm, double-stranded DNA, and alpha-fodrin (AF). AHA patients were more often positive for ANA than control patients (64% vs. 30%, odds ratio [OR] 4.02, 1.98-8.18) and had higher ANA titers detected than controls. Cytoplasmic autoantibodies and anti-AF IgA autoantibodies were also more frequent in AHA patients compared to controls. Autoantibodies against any target other than FVIII were found in 78% of AHA patients compared to 46% of controls (OR 4.16, 1.98-8.39). Results were similar preforming sensitivity analyses (excluding either subjects with autoimmune disorders, cancer, pregnancy, or immunosuppressive medication at baseline) and in multivariable binary logistic regression. To exclude that autoantibody staining was merely a result of cross-reactivity of anti-FVIII autoantibodies, we tested a mix of 7 well-characterized monoclonal anti-FVIII antibodies. These antibodies did not stain HEp-2 cells used for ANA detection. In conclusion, a diverse pattern of autoantibodies is associated with AHA, suggesting that a more general breakdown of immune tolerance might be involved in its pathology.

 

 

 

 

 

 


Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?

Hosoi H., Tane M., Kosako H., Ibe M., Takeyama M., Murata S., Mushino T., Sonoki T.
[In Process] J. Autoimmun. 2022 133:

Go to publisher for the full text

Abstract

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder. Various autoimmune diseases, including AHA, have been reported to occur after the administration of mRNA COVID-19 vaccines. However, the characteristics of these AHA cases remain unclear. We report a case in which AHA arose in a young patient after the administration of an mRNA COVID-19 vaccine, but improved rapidly. The patient's factor VIII (FVIII) inhibitor titer spontaneously decreased to less than half of that seen at diagnosis. One week after the initial immunosuppressive therapy, the FVIII inhibitor had disappeared. Our case suggests that AHA that arises in young patients after COVID-19 vaccination may resolve spontaneously, and the levels of FVIII inhibitors may decrease more rapidly in such cases than in idiopathic AHA. Unlike for immune thrombocytopenic purpura (ITP), no acute type of AHA has been recognized. This case suggests that just as there is an acute type of ITP that develops in children/after vaccination, there may be an acute type of AHA that arises in young patients that receive mRNA COVID-19 vaccines.


The value of radiosynoviorthesis for treatment of chronic synovitis in haemophilic joint disease

Horneff S., Boddenberg-Pätzold B.
[Article in Press] Q J Nucl Med Mol Imaging 2022 :

Go to publisher for the full text

Abstract

Chronic synovitis is contributing to the development of arthropathy in haemophilia A and B. In most patients with severe and moderate haemophilia, during lifetime, joint damage progresses despite early prophylaxis and intense treatment with coagulation factor concentrates. Recurrent haemorrhages into the joints and subclinical bleeding lead to chronic inflammation of the synovium, neoangiogenesis and remodeling, sustaining a vicious circle of bleeding-remodelingbleeding and progression of osteochondral damage. Imaging techniques including ultrasound and MRI are able to early visualize synovitis and osteochondral changes. Early detection and sustained therapy of synovitis are important preconditions to prevent further deterioration of joint status. Chronic synovitis requires intensified substitution of coagulation factors and concomitant analgetic, antiphlogistic and physical therapy. The value of early radiosynoviorthesis (RSO) as effective method to control ongoing synovitis is discussed here. RSO is recommended as first choice therapy in case of persistant chronic synovitis, recorded in both national and international guidelines.


Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ regulatory T cells

Becker-Gotot J., Meissner M., Kotov V., Jurado-Mestre B., Maione A., Pannek A., Albert T., Flores C., Schildberg F.A., Gleeson P.A., Reipert B.M., Oldenburg J., Kurts C.
[Article in Press] J Clin Invest 2022 :

Go to publisher for the full text

Abstract

A major complication of hemophilia A therapy is the development of alloantibodies (inhibitors) that neutralize intravenously administered coagulation factor VIII (FVIII). Immune tolerance induction therapy (ITI) by repetitive FVIII injection can eradicate inhibitors, and thereby reduce morbidity and treatment costs. However, ITI success is difficult to predict and the underlying immunological mechanisms are unknown. Here, we demonstrated that immune tolerance against FVIII under non-hemophilic conditions was maintained by programmed death (PD) ligand 1 (PD-L1)-expressing regulatory T cells (Treg) that ligated PD-1 on FVIII-specific B cells, causing them to undergo apoptosis. FVIII-deficient mice injected with FVIII lacked such Treg and developed inhibitors. Using an ITI mouse model, we found that repetitive FVIII injection induced FVIII-specific PD-L1+ Tregs and re-engaged removal of inhibitor-forming B cells. We demonstrated the existence of FVIII-specific Tregs also in humans and showed that such Tregs upregulated PD-L1 after successful ITI. Simultaneously, FVIII-specific B cells upregulated PD-1 and became killable by Tregs. In summary, we showed that PD-1-mediated B cell tolerance against FVIII operated in healthy individuals and in hemophilia A patients without inhibitors, and that ITI re-engaged this mechanism. These findings may impact monitoring of ITI success and treatment of hemophilia A patients.


An Update on Laboratory Diagnostics in Haemophilia A and B

Müller J., Miesbach W., Prüller F., Siegemund T., Scholz U., Sachs U.J.
Hamostaseologie 2022 42:4 (248-260)

Go to publisher for the full text

Abstract

Haemophilia A (HA) and B (HB) are X-linked hereditary bleeding disorders caused by lack of activity of coagulation factors VIII (FVIII) or IX (FIX), respectively. Besides conventional products, modern replacement therapies include FVIII or FIX concentrates with an extended half-life (EHL-FVIII/FIX). Two main strategies for measuring plasma FVIII or FIX activity are applied: The one-stage clotting assay (OSCA) and the chromogenic substrate assay (CSA), both calibrated against plasma (FVIII/FIX) standards. Due to the structural modifications of EHL-FVIII/FIX, reagent-dependent assay discrepancies have been described when measuring the activity of these molecules. Assay discrepancies have also been observed in FVIII/FIX gene therapy approaches. On the other hand, nonfactor replacement by the bispecific antibody emicizumab, a FVIIIa-mimicking molecule, artificially shortens activated partial thromboplastin time-based clotting times, making standard OSCAs inapplicable for analysis of samples from patients treated with this drug. In this review, we aim to give an overview on both, the currently applied and future therapies in HA and HB with or without inhibitors and corresponding test systems suitable for accompanying diagnostics.


THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA

Königsbrügge O., Rejtö J., Kraemmer D., Schuster G., Feistritzer C., Gebhart J., Ay C., Pabinger I.
HemaSphere 2022 6: (2919)

Go to publisher for the full text

Abstract

Background: Obesity leads to increased strain on muscles and joints and could be a contributing factor to the burden of disease in patients with non-severe hemophilia. Fatty tissue, however, also plays an active part in the production of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) and is considered to transition the balance of hemostasis towards a reduction of fibrinolysis. Aims: We aimed to investigate the effects of obesity on the frequency of bleeding and changes in parameters of fibrinolysis in persons with non-severe hemophilia. Methods: Persons with non-severe hemophilia A or B (PwH) were recruited into a cross-sectional cohort study after informed consent. Frequency of bleeding in the past 5 years was retrospectively recorded. Body-mass index (BMI), FVIII or IX activity, t-PA antigen and activity, and PAI-1 activity were measured. Results: The cohort includes 90 PwH (74 hemophilia A, 16 hemophilia B) with a median age of 49.6 years (25th to 75th percentile 34.5-59.9), and a median FVIII/FIX level of 12% (8-19%). The median BMI was 25.7 kg/m2 (23.3- 28.3), and 14 patients (15.5%) had BMI>30. The median number of bleeding episodes in the past 5 years was 0 (0-1). In age-adjusted negative binomial regression, factor VIII/IX level (incidence rate ratio [IRR] 0.93 per 1% increase, 95% confidence interval [CI] 0.88-0.98, p<0.001), and BMI (IRR 0.82 per 1kg/m2 increase, 95%CI 0.74-0.91, p<0.001) were independently associated with frequency of bleeding episodes. Factor VIII/IX levels (IRR 0.88, 95%CI 0.80-0.96, p=0.005) and BMI (IRR 0.68, 95%CI 0.55-0.82) were also independently associated with the frequency of joint and muscle bleeding. BMI correlated with PAI and t-PA antigen levels (rho 0.241, p= 0.025 and 0.257, p= 0.017) and correlated inversely with t-PA activity (rho -0.240, p=0.026). Summary/Conclusion: While level of FVIII or FIX are the main determinants of bleeding severity, there is considerable heterogeneity in the bleeding phenotype irrespective of factor level. We found that in non-severe hemophilia patients, increasing BMI decreased the number of bleeding episodes and joint and muscle specific bleeding episodes. The bleeding severity was potentially mitigated by increasing PAI levels and decreasing t-PA activity.


 

Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis

De la Corte-Rodriguez H., Rodriguez-Merchan E.C., Alvarez-Roman M.T., Martin-Salces M., Jimenez-Yuste V.
Haemophilia 2022 28:1 (138-144)

Go to publisher for the full text

Abstract

Background: The ability of clinical tools to identify early joint changes is limited. Synovitis is a fundamental finding in understanding haemophilia activity and the response to its therapies; thus, there is a need for sensitive methods to better diagnose subclinical synovitis early. Purpose: Our aim was to compare the frequency with which clinical assessment and ultrasound detected synovial hypertrophy in the most frequently affected joints in patients with haemophilia (elbows, knees and ankles). Methods: We analysed patients with haemophilia older than 16 years who came to the haemophilia centre for routine follow-up. From the clinical assessment carried out in the consultation, the swelling, pain and history of haemarthrosis were evaluated and compared with the findings of synovial hypertrophy detected by ultrasound. This comparison was also analysed independently for elbows, knees and ankles. Results: A total of 203 joints of 66 patients with haemophilia (mean age 34 years), most of them on secondary, tertiary prophylaxis or on demand treatment, were included. In joints with swelling, pain and history of haemarthrosis, 78% of the joints showed synovial hypertrophy on ultrasound. However, in joints with no swelling, no pain and no history of haemarthrosis, 40% presented subclinical synovial hypertrophy on ultrasound. This percentage was higher in elbows than in knees and ankles. Conclusion: In adults with haemophilia, physical examination and point-of-care ultrasound study provide complementary data on their joint disease. However, without ultrasound, the ability to detect subclinical synovitis is considerably reduced, especially in the elbows.

 


Managing Pregnant Women with Hemophilia and von Willebrand Disease: How Do We Provide Optimum Care and Prevent Complications?

Janbain M., Kouides P.
Int. J. Womens Health 2022 14: (1307-1313)

Go to publisher for the full text

Abstract

The challenge of pregnancy can be significant to the point of being life-threatening in a woman with a bleeding disorder. Additionally there can be a risk to the fetus and the neonate. A hemostatic defect can affect the course of the pregnancy, but the impact is most feared around delivery in the immediate and the extended post partum period, requiring rapid identification and prompt referral to a hematologist for assistance in management. Identifying the type of congenital bleeding disorder and knowing its inheritance pattern is crucial during counseling prior to conception and in preparation for delivery. A comprehensive approach by a specialized and experienced team in a tertiary care center with access to adequate laboratory monitoring and therapies can facilitate the process. The multidisciplinary team should include a hematologist, an obstetrician, a pediatric hematologist, an anesthesiologist, and in select cases a clinical geneticist and a maternal fetal medicine specialist. In this review article, we will detail the diagnostic path and management of pregnancy and delivery in women with some inherited bleeding disorders, in particular those affected by hemophilia A (HA), hemophilia B (HB), and von Willebrand disease (VWD).

 


 

The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study

Grazzi E.F., Sun S.X., Burke T., O’hara J.
[In Process] J. Blood Med. 2022 13: (505-516)

Go to publisher for the full text

Abstract

Background: Using a pharmacokinetic (PK)-guided approach to personalize the dose and frequency of prophylactic treatment can help achieve and maintain targeted factor VIII (FVIII) trough levels in patients with hemophilia A. Objective: Investigate clinical and healthcare resource use outcomes in patients with hemophilia A treated with or without PK-guided prophylaxis using data from the Cost of Haemophilia in Europe: A Socioeconomic Survey (CHESS) II database. Methods: CHESS II was a cross-sectional, retrospective, burden-of-illness study incorporating data from eight European countries. Patients were eligible for this analysis if they were male, ≥18 years of age, and diagnosed with congenital hemophilia A of any severity. The clinical endpoints included annualized bleeding rate (ABR), presence and number of problem/target joints, and occurrence of joint surgeries. Healthcare resource utilization endpoints included the number of hematologist consultations and bleed-related hospitalizations or emergency department admissions. Data from November 2018 to October 2020 were included and were stratified according to treatment regimen and use of PK-guided dosing. Results: Altogether, 281 patients on prophylaxis had available FVIII trough level data. Mean (SD) age was 35.7 (13.8) years. A specific FVIII trough level was targeted in 120 (42.7%) patients and 47 (39.2%) received PK-guided dosing. Patients receiving PK-guided dosing had a mean (SD) ABR of 2.8 (2.1) and target joint number of 0.5 (0.7), compared with 3.9 (2.7) and 0.9 (1.4), respectively, for patients receiving non–PK-guided treatment. The mean (SD) number of hematologist consultations was 7.1 (5.3) for patients receiving PK-guided dosing versus 10.7 (5.7) for those who were not. A higher proportion of patients in the non–PK-guided group required hospitalization during their lifetime compared with the PK-guided group. Conclusion: This analysis of real-world data suggests that PK-guided dosing for prophylaxis has a beneficial impact on clinical and healthcare resource utilization outcomes in patients with hemophilia A.

 

 


WFH Guidelines for the Management of Hemophilia, 3rd edition

Srivastava A., Santagostino E., Dougall A., Kitchen S., Sutherland M., Pipe S.W., Carcao M., Mahlangu J., Ragni M.V., Windyga J., Llinás A., Goddard N.J., Mohan R., Poonnoose P.M., Feldman B.M., Lewis S.Z., van den Berg H.M., Pierce G.F.
Haemophilia 2020 26:S6 (1-158)

Go to publisher for the full text